BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

Core Insights - BioAtla, Inc. is presenting clinical data on its investigational antibody-drug conjugate, ozuriftamab vedotin (Oz-V), at the International Papillomavirus Society Conference, focusing on its application in treating advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC) [1][2] Company Overview - BioAtla is a global clinical-stage biotechnology company based in San Diego, California, and Beijing, China, specializing in the development of Conditionally Active Biologic (CAB) antibody therapeutics [6] - The company utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting and greater efficacy with lower toxicity [6] Product Details - Ozuriftamab vedotin (Oz-V) targets ROR2, a receptor tyrosine kinase overexpressed in various solid tumors, including OPSCC, driven by HPV infection [4] - In a Phase 2 trial, Oz-V demonstrated an overall response rate (ORR) of 45% and a disease control rate (DCR) of 100% in refractory patients, with a median overall survival (OS) of 11.6 months [4] - The FDA has granted Fast Track Designation to Oz-V for treating recurrent or metastatic squamous cell carcinoma of the head and neck [4] Market Opportunity - The global market opportunity for second-line and beyond OPSCC is over $1 billion, while for first-line HPV+ tumors, it is potentially over $7 billion [5] - OPSCC is rapidly increasing, with HPV infections accounting for approximately 80% of cases in the United States [5]